- Fight acne no matter
where you are!
Learn more about participating in this acne research study from the comfort of your own home.
- We’re hiring
Start a new career
Find out about new opportunities to be kind, useful and awesome at Science 37!
- Accelerating research
to find cures faster
We simplify the process of participating in trials and connect patients to the world's best scientists, no matter where they live.
- Are you or a loved one
living with cancer
Learn more about participating in this cancer research study from the comfort of your own home.
What is NORA®?
Patient Centered Design
Watch Our Videos
Clinical Research for Patients
The promise of a Science 37 managed clinical research trial centers on a mobile technology platform combined with high quality patient care. Our proprietary Metasite™ operating model reinvents the clinical trial process by connecting patients, care providers, clinical investigators and research sponsors towards the same goal – faster, less expensive clinical trials for the introduction of new therapies sooner.
The Gift of Hope
A patient's journey with a rare disease tells the story of participating in a Science 37-enabled clinical research trial. The hope for a better future and a rewarding experience of contributing to scientific knowledge are among the benefits.
What is NORA®
NORA® stands for Network Oriented Research Assistant, and is the HITECH certified 21 CFR Part 11 compliant technology platform that allows Science 37 to bring research directly to patients in their own homes. NORA® integrates telemedicine technology into the clinical research process, and supports Science 37’s end-to-end management of clinical trials. From the first steps of trial design, to connecting with patients at home, NORA® is there to help. Contact us to learn more.
Impact of the Science 37 Approach
Metasite™-enabled clinical trials remove geographic barriers and unlock access to patients no matter where they live. Decentralizing the clinical trial away from traditional site-based centers eliminates critical barriers to rapid, cost-effective patient enrollment. Barriers include inaccessibility due to geography, lack of patient awareness and trust, and the inconvenience posed by site visits. Metasites increase the speed of trials by designing study activities around the lives of patients.
You may be eligible to take part in a Science 37 trial. Learn more about how to participate.Read More
Learn how to accelerate your clinical trial.
Science 37 offers end-to-end clinical trial services from protocol design and regulatory strategy to recruitment strategies and remote execution. Experience a truly connected clinical trial research process, from digitally enabled data collection, transfer, analysis and storage to trials by design that connect and recruit patients no matter where they live. Work with us to accelerate discovery and improve patient health.
You have the ability to reach patients across a broader geography and from a more diverse patient population. Join the Science 37 Team.
Science 37’s high-tech and high-touch research services allow you to focus on what matters – the patient. Mobile technology and a dedicated research staff enable clinical trial participation from home keeping clinicians connected to the patient. A network of mobile nurses and existing healthcare providers supports real-time communication to ensure appropriate study execution and patient safety.
Meet the Virtual Trial Specialists
- Trial Team (35)
- Physician Experts (35)
- Technology Team (9)
- Administrative Team (9)
- Leadership Team (12)
- Board of Directors (7)
- Advisors (5)
- All (103)
Science 37 Secures $31M Series B Funding to Expand Clinical Trial Access to Anyone, Anywhere, AnytimeLOS ANGELES, Oct. 18, 2016 /PRNewswire/ -- Science 37 (http://www.science37.com), a technology-enabled clinical research company, today announced that it has completed a $31 million Series B financing. Science 37 is reimagining clinical research by bringing clinical trials to people's homes, which unlocks access to those beyond a geographical barrier. The investment will help the company grow operations, further develop its novel technology platform and continue to expand into new therapeutic areas. The Series B financing was…
Science 37 Named Clinical Informatics News Best Practices Award WinnerAt the heart of faster cures and better treatments is clinical research. It is the process through which new drugs, medical devices and biologics are brought to market. It is the way in which we advance medicine to deliver improvements in care and hope for a healthier tomorrow.
Science 37 Named in Top 40 Healthcare Transformers ListThere is no denying that technology has transformed nearly every aspect of our daily lives – from how we communicate, to the way we travel, to the process through which we make decisions. Indeed, even regulated industries, typically slow to move and resistant to change, have begun to embrace disruption
Science 37 Secures $6.5M Series A Funding To Accelerate Clinical Trial ResearchScience 37 (http://science37.com), a technology-enabled clinical research company, today announced the completion of a $6.5 million Series A financing co-led by Lux Capital and dRx Capital. The investment will accelerate Science 37’s development and rollout of its new operating model, which solves some of the greatest inefficiencies in conducting clinical trials.
Science 37 Named Disruptive Innovator of the Year at DPharm 2015
Science 37 and Precision MedicineScience 37 CEO and Co-Founder Noah Craft, MD, PhD submitted the following comments on the White House website's Precision Medicine Initiative Page.
Science 37 wins Clinical Trial Innovation PrizeIn honor of World Cancer Day 2015, the Bonnie J. Addario Lung Cancer Foundation and Free To Breathe, with support from Celgene and Genentech, created the Clinical Trial Innovation Prize. The ultimate goal of the challenge is to produce a breakthrough that doubles the accrual rate of lung cancer clinical trials. We couldn’t be happier to have been selected as one of 12 finalists and awarded one of the first three prizes in “Ideation” phase of the program.
Science 37 and LA BioMed launch telemedicine substudy arm of global PEMPHIX trialLA BioMed and Science 37 have launched their first collaborative clinical research trial and enrolled patients in the first-ever virtual, networked clinical trial using telemedicine to monitor the effects of an infusion medication. The research study will compare the effects of rituximab with another medication called mycophenolate mofetil in treating adults with active pemphigus vulgaris (PV). Pemphigus vulgaris is an auto-immune skin condition that causes your skin to form blisters. LA Biomed is one of more than 60 sites for the PEMPHIX clinical trial, sponsored by Genentech, and the only telemedicine-based site.